144 related articles for article (PubMed ID: 9332764)
1. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
4. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
5. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
7. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas.
Ramondetta LM; Palazzo JP; Dunton CJ; Kovatich AJ; Carlson JA
Anticancer Res; 1998; 18(6B):4661-5. PubMed ID: 9891537
[TBL] [Abstract][Full Text] [Related]
9. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure.
Fles R; Hoogendoorn WE; Platteel I; Scheerman CE; de Leeuw-Mantel G; Mourits MJ; Hollema H; van Leeuwen FE; van Boven HH; Nederlof PM
Genes Chromosomes Cancer; 2010 Aug; 49(8):699-710. PubMed ID: 20544844
[TBL] [Abstract][Full Text] [Related]
10. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients.
Robinson DC; Bloss JD; Schiano MA
Gynecol Oncol; 1995 Nov; 59(2):186-90. PubMed ID: 7590470
[TBL] [Abstract][Full Text] [Related]
12. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F
Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
14. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
Freedman AN; Michalek AM; Marshall JR; Mettlin CJ; Petrelli NJ; Black JD; Zhang ZF; Satchidanand S; Asirwatham JE
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):285-91. PubMed ID: 8722220
[TBL] [Abstract][Full Text] [Related]
15. Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women.
Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):255-63. PubMed ID: 10090304
[TBL] [Abstract][Full Text] [Related]
16. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
17. [Pathology of the endometrium in breast cancer patients treated with tamoxifen (nolvadex)].
Ivanova V; Karaivanov M; Marinov E; Gorchev G; Velkova A; Khristova P
Akush Ginekol (Sofiia); 2003; 42(5):3-8. PubMed ID: 14682005
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.
Conway K; Edmiston SN; Cui L; Drouin SS; Pang J; He M; Tse CK; Geradts J; Dressler L; Liu ET; Millikan R; Newman B
Cancer Res; 2002 Apr; 62(7):1987-95. PubMed ID: 11929815
[TBL] [Abstract][Full Text] [Related]
19. Stroke risk and tamoxifen therapy for breast cancer.
Geiger AM; Fischberg GM; Chen W; Bernstein L
J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
[TBL] [Abstract][Full Text] [Related]
20. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]